How to Cite
Abstract
In this study we evaluated clinical value of mammoscintigraphy (MSG) with 99mTc-MIBI when it was performed after 2-3 cycles of neoadjuvant chemotherapy (NAC) and then before the surgery. In 86 women included in the study scintigraphic signs of tumour progression or stabilization were detected in 42 (48. 9%) cases. In another 29 patients after 2-3 cycles of NAC results of MSG pointed out partial response. The most promising group consisted of 15 women with prominent or complete response in the middle (2-3 cycles) of NAC. We proposed that these patients can be good candidates for consolidative radiotherapy instead of surgical treatment.References
Брянцева Ж.В., Канаев С.В., Семиглазов В.Ф. и др. Роль сцинтиграфии молочных желез с 99mTc-технетрилом для прогнозирования патоморфологического статуса регионарных лимфатических узлов у больных местно-распространенным раком молочной железы после проведения неоадьювантной химиотерапии // Вопр. онкол. - 2015. - Т. 61.- № 2. - С. 185-188.
Канаев С.В., Криворотько П.В., Новиков,С.Н. и др. К вопросу о возможности применения маммосцинтиграфии для контроля эффективности неоадъювантной полихимиотерапии больных раком молочной железы // Вопр. онкол. - 2013. - Т. 59. - № 3 - С. 328-333.
Портной С.М., Оджарова А.А., Ширяев С.В. и др. Предварительные результаты использования 99mТс-технетрила при прогнозироваНИИ эффекта предоперационной химиотерапии местнораспространенного рака молочной железы // Вопр. онкол. - 2006. - Т. 52. - № 6. - С. 620-623.
Тицкая А.А., Чернов В.И., Синилкин И.Г. и др. Стандартизированные методики радионуклидной диагностики. Маммосцинтиграфия // Москва. - 2014. - С. 1-32.
Чернов В.И., Тицкая А.А., Синилкин И.Г., Зельчан Р.В. Сцинтиграфия молочных желез. Рекомендации к выполнению исследования // Лучев. диагност. терап. - 2013. - № 1 (4). - С. 93-98.
Bonadonna G., Valagussa P., Brambilla C. et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute // J. Clin. Oncol. - 1998. - Vol. 16. - P. 93-100.
De Boer R.H., Allum W.H., Ebbs S.R. et al. Multimodality therapy in inflammatory breast cancer: is there a place for surgery? // Ann.Oncol. - 2000. - Vol. 11. - P. 11471153.
Fisher B., Gunduz N., Saffer E.A. Influence of thre interval between primary tumor removal and chemotherapy on kinetics and grows of metastases // Cancer Res. -1983. - Vol. 43. - P. 1488-1492.
Londero V., Bazzocchi M., Frate C. et al. Locally advanced breast cancer: cjparison ofmammmography, sonography and MR imaging in evaluation residual disease in women receiving neoadjuvant chemotherapy // Eur. Radiol. - 2004. - Vol. 14. - P. 1371-1379.
Mauri D., Pavlidis N., loannidis P.A. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis // J Natl Cancer Inst Monogr. - 2005. - Vol. 97. - P 188-194.
Mauriac I., Mac Grogan G., Avrl A. et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trialwith 124 month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) // Ann. Oncol. -1999. - Vol. 10. - P 47-52.
Neuschatz AC, DiPetrillo T, Safaii H. et al. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy // Cancer. - 2003. - Vol. 97. - P. 30-39.
Ring A., Ashley W.S., Allum W.H. et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? // J.Clin.Oncol. -2003. - Vol. 21. - P. 4540-4545.
Smith I.C., Heys S.D., Hutcheon A.W. et al. Neoadjuvant chemotherapy in breast cancer significantly enhanced response to doxetaxel // J.Clin.Oncol. - 2002.- Vol. 20. - P 1456-1466.
Stephen V.L., Melstrom L., Yao K. et al. Neoadjuvant therapy for breast cancer // J.Surg.Oncol. - 2010. - Vol. 101. - P. 283-291.
Scholl S.M., Fourquet A., Asselain B. et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast concerving surgery: preliminary results of a randomized trial: S6 // Eur. J. Cancer. -1994. - 30A. - P. 645-652.
Thomas E., Holmes F.A., Smith T.L. et al. the use of alteranate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in woman with operable breast cancer: long-term results from prospective randomized trial // J.Clin.Oncol. - 2004.- Vol. 22. - P. 2294-2302.
Von Minckwitz G., Biohmer J.U., Costa S.D. et al. Response -guided neoadjuvant chemotherapy for breast cancer // J.Clin.Oncol. - 2013. - Vol. 31. - P. 3623-3630
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...